Novo Nordisk (NVO) shares are slimming down. Shares of the Wegovy maker tanked more than 5% on Monday as the company failed to impress Wall Street at its capital markets day. The company came up short by not sharing more specifics around near-term growth targets amid fierce competition in the weight loss drug market. The company said it's targeting more than $23 billion in pipeline sales by 2035. It has plans to launch more than five potential multi-blockbusters by the end of the decade. (NVO ) Go deeper with AlphaSpace 43.24 +0.05 (+0.12%) At close: September 18 at 4:04:12 PM EDT "We have a situation where competition, as we are seeing it, has never been at least in Novo's historical back.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.